Boston Hub
Boston Hub
Comprising sites in Rockland, Billerica and Cambridge, Merck Serono’s R&D activities at this hub are built on a foundation of expertise in Rheumatology, Fertility, Neurodegenerative Diseases and Oncology. Our scientists apply their know-how across a variety of areas critical for successful drug discovery and development, including pharmacology, chemistry, bioinformatics, biotechnology, pharmacokinetics, pharmacogenetics, clinical operations, regulatory affairs, quality assurance and drug safety.
An investment of USD 65 million in a new state-of-the-art research facility in Billerica (northwest of Boston) highlights our commitment to innovative drug discovery research in Neurodegenerative Diseases, Oncology and Fertility at this site.
An investment of USD 65 million in a new state-of-the-art research facility in Billerica (northwest of Boston) highlights our commitment to innovative drug discovery research in Neurodegenerative Diseases, Oncology and Fertility at this site. This new center of excellence offers capacity for more than 300 researchers. It is designed to attract the very best scientific talent and underpin a broad range of partnerships with US-based companies, academic centers and key opinion leaders in these therapeutic areas.
“Here, I am applying my knowledge to discovering or improving therapies for serious diseases. That’s a whole different level of motivation. By changing the structure of a protein molecule, it’s possible to improve its function as a medical therapy, for cancer say, or for autoimmune diseases.”
Vanita, Senior Scientist, Protein Engineering & Antibody Technologies, EMD Serono, Billerica, USA
Vanita, Senior Scientist, Protein Engineering & Antibody Technologies, EMD Serono, Billerica, USA
